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Distinct parameters of the basophil activation test reflect
the severity and threshold of allergic reactions to peanut
Alexandra F. Santos, MD, MSc,a,b,c,d George Du Toit, FRCPCH,a,b Abdel Douiri, PhD,e,f Suzana Radulovic, MD,a,b
Alick Stephens, PhD,a,b Victor Turcanu, PhD,a,b and Gideon Lack, MD, FRCPCHa,b London, United Kingdom, and Coimbra
and Lisbon, PortugalBackground: The management of peanut allergy relies on
allergen avoidance and epinephrine autoinjector for rescue
treatment in patients at risk of anaphylaxis. Biomarkers of
severity and threshold of allergic reactions to peanut could
significantly improve the care for patients with peanut allergy.
Objective: We sought to assess the utility of the basophil
activation test (BAT) to predict the severity and threshold of
reactivity to peanut during oral food challenges (OFCs).
Methods: The severity of the allergic reaction and the threshold
dose during OFCs to peanut were determined. Skin prick tests,
measurements of specific IgE to peanut and its components, and
BATs to peanut were performed on the day of the challenge.From athe Department of Pediatric Allergy, Division of Asthma, Allergy & Lung
Biology, King’s College London; bMRC & Asthma UK Centre in Allergic Mecha-
nisms of Asthma, London; cthe Immunoallergology Department, Coimbra University
Hospital; dGulbenkian Programme for Advanced Medical Education, Lisbon; ethe
Department of Public Health Science, School of Medicine, King’s College London;
and fthe National Institute for Health Research (NIHR), Biomedical Research Centre,
Guy’s and St Thomas’ NHS Foundation Trust, London.
Supported by the Medical Research Council (G0902018), Goldman Sachs Gives, and the
Department of Health through the National Institute for Health Research (NIHR)
comprehensive Biomedical Research Centre award toGuy’s&St Thomas’ NHS Foun-
dation Trust in partnership with King’s College London and King’s College Hospital
NHS Foundation Trust. The views expressed are those of the author(s) and not neces-
sarily those of the NHS, the NIHR, or the Department of Health. The clinical trials unit
is supported by the National Peanut Board, Atlanta, Ga. The Programme for Advanced
Medical Education is sponsored by Fundac¸~ao Calouste Gulbenkian, Fundac¸~ao Cham-
palimaud, Ministerio da Saude and Fundac¸~ao para a Cie^ncia e a Tecnologia, Portugal.
Disclosure of potential conflict of interest: This studywas funded by theMedical Research
Council (G0902018), Goldman Sachs Gives, and the Department of Health through the
National Institute for Health Research in partnership with King’s College London and
King’s College Hospital NHS Foundation Trust. A. F. Santos and her institution have
received funding from the Medical Research Council (G0902018), the National Peanut
Board, the ImmuneToleranceNetwork/National Institute of Allergy and Infectious Dis-
eases (ITN032AD and ITN049AD), the Medical Research Council (MRC Centenary
Early Career Award), and the National Institute for Health Research and has received
support for travel and other meeting-related purposes from the European Academy of
Allergy and Clinical Immunology (EAACI) and the American Academy of Allergy
Asthma and Immunology. G. Du Toit is employed by St Thomas’ Hospital, a National
Health Service (NHS) teaching hospital, which has received funding from the Immune
Tolerance Network (ITN032AD and ITN049AD) and received compensation for deliv-
ering lectures at the Annual Swineford Conference and for travel and other meeting-
related expenses from the EAACI. A. Douiri’s institution has received funding from
the National Institute for Health Research. S. Radulovic is employed by Kings College
London. G. Lack’s institution has received funding from the Immune Tolerance
Network (ITN032AD and ITN049AD), supported by the National Institute of Allergy
and Infectious Diseases, as well as the National Peanut Board and the Department of
Health, and he holds stock/stock options in DBV Technologies. The rest of the authors
declare that they have no other relevant conflicts of interest.
Received for publication July 29, 2014; revised August 27, 2014; accepted for publica-
tion September 2, 2014.
Corresponding author: Gideon Lack, MD, FRCPCH, Department of Pediatric Allergy, St
Thomas’ Hospital, 2nd Floor, Stairwell B, South Wing, Westminster Bridge Rd, Lon-
don SE1 7EH, United Kingdom. E-mail: gideon.lack@kcl.ac.uk.
0091-6749
 2014 The Authors. Published by Elsevier Inc. on behalf of the American Academy
of Allergy, Asthma & Immunology. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).
http://dx.doi.org/10.1016/j.jaci.2014.09.001Results: Of the 124 children submitted to OFCs to peanut, 52
(median age, 5 years) reacted with clinical symptoms that
ranged from mild oral symptoms to anaphylaxis. Severe
reactions occurred in 41% of cases, and 57% reacted to 0.1 g or
less of peanut protein. The ratio of the percentage of CD631
basophils after stimulation with peanut and after stimulation
with anti-IgE (CD63 peanut/anti-IgE) was independently
associated with severity (P 5 .001), whereas the basophil
allergen threshold sensitivity CD-sens (1/EC50 3 100, where
EC50 is half maximal effective concentration) value was
independently associated with the threshold (P 5 .020) of
allergic reactions to peanut during OFCs. Patients with CD63
peanut/anti-IgE levels of 1.3 or greater had an increased risk of
severe reactions (relative risk, 3.4; 95% CI, 1.8-6.2). Patients
with a CD-sens value of 84 or greater had an increased risk of
reacting to 0.1 g or less of peanut protein (relative risk, 1.9; 95%
CI, 1.3-2.8).
Conclusions: Basophil reactivity is associated with severity and
basophil sensitivity is associated with the threshold of allergic
reactions topeanut.CD63peanut/anti-IgEandCD-sens values can
be used to estimate the severity and threshold of allergic reactions
during OFCs. (J Allergy Clin Immunol 2015;135:179-86.)
Key words: Basophil activation test, peanut, peanut allergy,
threshold, severity, sensitivity, CD63, CD203c, CD-sens, double-
blind, placebo-controlled food challenge
Peanut allergy (PA) affects about 1.4% of children in the
United States and 2% of children in the United Kingdom and is
the most common cause of life-threatening anaphylaxis in
childhood.1,2 The increase in hospitalization rates for peanut-
induced anaphylaxis seems to follow the increase in the preva-
lence of PA.3 Patients often have a severe reaction on their first
exposure to peanut.4 Oral food challenges (OFCs), the gold stan-
dard for diagnosis of PA, can also cause severe reactions in a sig-
nificant proportion of cases.5 There is no curative treatment for
PA, and the mainstay of its management is allergen avoidance
and use of an epinephrine autoinjector as rescue treatment in se-
vere cases. Allergen avoidance is difficult, and accidental allergic
reactions are common.6 Patients with PA often react to small
amounts of the allergens with symptoms that can be life-
threatening, and thus PA has a negative effect on quality of life
in patients and their families.
Current recommendations for the management of food allergy
and anaphylaxis are based on expert opinion more than evidence-
based randomized controlled trials.7-9 Various clinical factors
have been identified as conferring a greater risk for severe food-
induced allergic reactions, namely a previous history of anaphy-
laxis and the coexistence of uncontrolled asthma.4 However,
most patients with fatal or near-fatal anaphylaxis had a history
of mild allergic reactions, and not all had asthma.10,11 Therefore179
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180 SANTOS ET ALAbbreviations usedCD63 peanut/anti-IgE: Ratio of the percentage of CD631 basophils at
100 ng/mL of peanut extract to the percentage
of CD631 basophils after stimulation with
anti-IgECD-sens: Basophil allergen threshold sensitivityDBPCPC: Double-blind, placebo-controlled peanut
challengeEC50: Half maximal effective concentrationLEAP: Learning Early About Peanut AllergyPA: Peanut allergyPE: Peanut extractSPT: Skin prick testan objective biomarker that could accurately reflect the likelihood
of experiencing severe allergic reactions for individual patients
would be useful to help define indications for the prescription of
an epinephrine autoinjector and help with risk assessment in
patients who have to undergo an OFC for diagnostic purposes.
Thus far, no reliable markers of severity or threshold have been
identified. A recent article in this journal examined predictors of
severity and threshold, including BATs in patients with PA, as
confirmed based on challenge results.12 The authors found that no
single parameter correlated with severity and that several param-
eters correlated with threshold doses.
Determining peanut threshold doses and whether a patient is
likely to react to trace amounts of the allergen is an important
aspect of the management of PA. Individual peanut thresholds
could help define the stringency of allergen avoidance measures,
and population peanut thresholds would be useful for public
health authorities and the food industry to establish regulatory
measures to protect patients with food allergy and institute
allergen control measures and labeling policies. The current
gold standard to determine threshold doses is a graded double-
blind, placebo-controlled peanut challenge (DBPCPC) in patients
known to have peanut allergy.13 This is logistically and techni-
cally demanding and carries significant risk; therefore an
ex vivo method that could estimate threshold levels without the
need for a DBPCPC would be very valuable.
We recently showed that the basophil activation test (BAT)
reproduces very closely the phenotype of peanut-sensitized
patients in relation to allergy versus tolerance.14 Basophils and
mast cells are the effector cells of anaphylaxis. Basophils seem
to be particularly relevant in patients with food-induced anaphy-
laxis, which often occurs without increased serum tryptase levels.
Different methods to express the results of the BAT based on the
allergen-induced dose-response curve reflect different aspects of
the basophil response. The percentage of activated basophils mea-
sures basophil reactivity (eg, %CD631 basophils at different
allergen concentrations; the maximal %CD631 basophils
[maximal reactivity, CD-max] or the ratio of the %CD631 after
stimulation with allergen and with anti-IgE), and the concentra-
tion of allergen at which basophils become activated measures
basophil sensitivity to the allergen (eg, EC5, EC10, EC50, CD-
sens).15 We hypothesized that patients with severe reactions
would show greater basophil reactivity and that patients who
respond to lower doses of peanut allergen would show greater
basophil sensitivity. We anticipated that higher percentages of
activated basophils would result in higher percentages of baso-
phils degranulating and higher amounts of vasoactive mediatorsreleased, leading to more severe symptoms. We anticipated also
that the threshold dose for basophil activation and degranulation
in vitro during the BAT would correspond to the threshold dose
in vivo during the challenges.METHODS
Study population
Consecutive patients participating in a study about use of the BAT in the
diagnosis of PA14 or in the Peanut Allergy and Sensitization study (which
included children who had been excluded from the Learning Early About Pea-
nut Allergy [LEAP] study16) with a positive oral peanut challenge result were
included in this study. On the same day and before the challenge, all children
underwent clinical evaluation, skin prick tests (SPTs), and blood collection for
specific IgE determination and BATs. The study was approved by the South
East London Research Ethics Committee 2.Written informed consent was ob-
tained from the parents of all participants.SPTs and serum specific IgE measurement
SPTs were performed by using a commercially available peanut extract
(PE; ALK-Abello, Hørsholm, Denmark), as previously described.14 Serum
specific IgE levels to peanut and to the recombinant peanut allergens rAra h
1, rAra h 2, rAra h 3, rAra h 8, and rAra h 9 were measured with an immunoen-
zymatic assay (ImmunoCAP; Thermo Fisher Scientific, Waltham, Mass).BAT
The BAT was performed, as previously described.14 Heparinized whole
blood was stimulated for 30 minutes at 378C with PE (ALK-Abello) diluted
in RPMImedium at serial 10-fold dilutions from 10mg/mL to 0.1 ng/mL. Poly-
clonal goat anti-human IgE (Sigma-Aldrich, St Louis, Mo), monoclonal mouse
anti-human FcεRI (eBioscience, San Diego, Calif), formyl-methionyl-leucyl-
phenylalanine (Sigma-Aldrich), or RPMI alone were used as controls. Cells
were stained with CD123–fluorescein isothiocyanate (eBioscience), CD203c-
phycoerythrin, HLA-DR–peridinin-chlorophyll-protein complex, and CD63-
allophycocyanin (BioLegend, San Diego, Calif), and erythrocytes were lysed.
Basophils were gated as low side scatter/CD203c1/CD1231/HLA-DR2. Baso-
phil expression of CD63 and CD203c was evaluated with the FACSCanto II
with FACSDiva software (BD Biosciences, San Jose, Calif). Data were
analyzed with FlowJo software, version 7.6.1 (TreeStar, Ashland, Ore).Oral peanut challenges and determination of
severity and threshold
Six verum doses and 3 placebo doses were randomly interspersed with
verum doses up to a cumulative dose of 9.35 g of peanut protein (see Table E1
in this article’s Online Repository at www.jacionline.org). Children 1 to 3
years of age were given 5 verum doses and 1 placebo dose up to a cumulative
dose of 4.35 g of peanut protein. High-risk patients (ie, patients with sus-
pected PA, a history of life-threatening food-induced anaphylaxis, or an
SPT response >_7 mm) received an additional lower starting active dose of
0.033 g of peanut protein. DBPCPCs were performed in 92% of cases.
Four patients had open challenges for logistic reasons, as previously re-
ported.14 The challenge result was considered positive only when objective
signs of an allergic reaction developed (see Table E2 in this article’s
Online Repository at www.jacionline.org) and the symptoms were treated.
In the case of a reaction after a placebo dose, the OFC was repeated with a
2-day protocol (1 day of placebo and 1 day of verum); otherwise, OFCs
were performed in a single day.17
Allergic reactions to peanut during challenges were attributed a symptom
score varying between 1 and 5, and the severity was classified into mild,
moderate, or severe categories by using a published method.18 Patients were
dichotomized depending on whether their reaction was mild-moderate or se-
vere (see Table E3 in this article’s Online Repository at www.jacionline.org).
Severity was classified by using 4 additional severity scores.19-22
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dose of peanut protein at the time of the reaction as opposed to a discrete
threshold dose. Patients were grouped according to the cumulative threshold
dose at the time of reaction into low (<_0.1 g of peanut protein) versus high
(>0.1 g of peanut protein) threshold doses. Discrete threshold doses (ie, the
dose administered immediately before the positive response) were also
recorded.23Statistical analysis
We predicted that severity would be related to basophil reactivity and that
threshold would be related to basophil sensitivity. We decided to look
primarily at the proportion of activated basophils at different peanut
concentrations and CD63 peanut/anti-IgE for severity and at half maximal
effective concentration (EC50) and basophil allergen threshold sensitivity
(CD-sens) values for threshold and also at other markers, such as the area un-
der the dose-response curve.15
Qualitative variables were represented as proportions and compared
between severity or threshold groups by using the Fisher exact test.
Continuous variables were represented as medians and interquartile ranges
and compared with the Mann-Whitney U test.
Allergy test parameters noted to have differences (P < .1) between groups
were further tested as independent variables in logistic regression analyses by
using the severity- or threshold-dichotomized groups as dependent variables.
The best performing BAT parameter (based on the lowest P value) was tested
in the logistic regression analysis: for severity, this parameter was the ratio of
the percentage of CD631 basophils at 100 ng/mL of PE to the percentage of
CD631 basophils after stimulation with anti-IgE (CD63 peanut/anti-IgE),
and for threshold, this parameter was CD-sens, which was determined by us-
ing CD63 (CD-sens is the inverse of the half-maximal effective concentration
[ie, the concentration at which basophil activation is half of themaximum acti-
vation] times 100 and can be calculated by using the following formula:
CD-sens 5 1/EC50 3 100), as previously described by Johansson et al.
24 In-
dependent associations between severity or threshold and allergy test param-
eters were further investigated by using multivariable logistic regression
analyses, and only variables significantly contributing to the model (P < .05)
were retained.
Patients were dichotomized based on the 75th percentile of CD63 peanut/
anti-IgE or CD-sens values and the proportion of patients with severe
reactions or low thresholds were compared between those falling above and
below the 75th percentile to quantify the differences in basophil activation
between severity and threshold groups. BAT cutoffs for severity and
threshold were also determined by using receiver operating characteristic
curve analyses.
The correlation between the clinical and diagnostic test parameters for
severity and threshold were assessed by using Spearman correlation.
Statistical analyses were performed with SPSS 22.0 software for Windows
(SPSS, Chicago, Ill) andMedCalc 13.3 (MedCalc Software, Ostend, Belgium).
P values of less than .05 were considered statistically significant.RESULTS
Study population
One hundred twenty-four patients were submitted to oral
peanut challenges. Fifty-two (42%) patients had a positive
challenge result to peanut. Three patients showed nonresponder
basophils and were excluded from further analyses. The study
population (n 5 49, Table I) was aged from 1.6 to 13 years (me-
dian age, 5 years), and the majority (77%) had never ingested pea-
nut before the challenge.Severity of allergic reactions during peanut
challenges
Symptoms during the challenge ranged from mild oral
symptoms to anaphylaxis. Twenty (41%) patients had severereactions (see Table E4 in this article’s Online Repository at www.
jacionline.org). Nine (18%) patients required the administration
of intramuscular epinephrine, and 10 (77%) required the admin-
istration of intravenous fluid boluses. One patient had a biphasic
reaction about 5 hours after the resolution of the allergic symp-
toms that occurred during the challenge.
Severe reactors had comparable SPT responses (P5 .102) and
higher levels of specific IgE to peanut (P 5 .010), Ara h 1 (P 5
.021), and Ara h 2 (P 5 .003) compared with the patients who
had mild-to-moderate reactions. Having a greater number of
peanut major allergens (Ara h 1, Ara h 2, and Ara h 3) recognized
by patients’ IgE was also associated with severe reactions (P 5
.019). Patients who received intramuscular epinephrine had
higher specific IgE levels to peanut (P 5 .031) and Ara h 2
(P 5 .011) than patients who did not require epinephrine (see
Table E4).Threshold of allergic reactions during peanut
challenges
The cumulative threshold dose of peanut protein varied
between 0.033 and 9.35 g (median, 0.1 g). Twenty-eight (57%)
patients reacted to 0.1 g or less of peanut protein during the
OFCs (see Table E4) and had larger wheals on SPTs to peanut
(P 5 .021) and higher levels of specific IgE to peanut (P 5
.026) and Ara h 2 (P 5 .032) than patients who reacted to
more than 0.1 g of peanut protein (Table I). Interestingly, pa-
tients with a higher cumulative peanut threshold dose had a
higher ratio of peanut-specific IgG4 to IgE (P 5 .011). Classi-
fying patients according to the discrete threshold dose of peanut
protein at the time of the reaction yielded similar findings (data
not shown).Severity of allergic reactions to peanut is associated
with greater allergen-specific basophil reactivity
Patients with severe reactions to peanut during OFCs showed a
higher proportion of CD631 basophils at concentrations of PE
ranging from 1 to 10,000 ng/mL compared with patients with
PA with mild-to-moderate reactions (P 5 .003-.049; Fig 1, A,
and Table II). The best basophil markers for the severity of
allergic reactions, based on the lowest P value, were the ratio of
the percentage of CD631 basophils at 100 ng/mL peanut to the
percentage of CD631 basophils after stimulation with anti-IgE
(CD63 peanut/anti-IgE, P < .001; Fig 2, A, and Table II) and the
percentage of CD631 basophils at 100 ng/mL PE (P 5 .003).
The latter marker was previously identified as optimal for the
diagnosis of PA14 and was the best discriminator of the patients
who had severe reactions requiring the administration of intra-
muscular epinephrine (see Table E5 in this article’s Online
Repository at www.jacionline.org).Basophil sensitivity indicates the threshold of
allergic reactions to peanut
The dose response for peanut-induced basophil activation of
patients with lower cumulative peanut threshold doses on OFCs
was shifted to the left compared with the dose response of patients
with a higher cumulative peanut threshold dose (Fig 1, B). Pa-
tients with PAwith lower threshold doses showed higher basophil
sensitivity, as expressed by a higher CD-sens value (P5 .005) and
TABLE I. Characteristics of the study population according to severity and threshold groups
Demographic features
and investigations
Study population
(n 5 49)
Severity groups Threshold groups
Mild-moderate
(n 5 29)
Severe
(n 5 20) P value
<_0.1 g Peanut
protein (n 5 28)
>0.1 g Peanut
protein (n 5 21) P value
Age (y) 5.4 (4.7-5.9) 5.2 (4.4-5.8) 5.4 (5.0-6.2) .250 5.3 (4.8-5.8) 5.4 (4.6-6.1) .928
Male sex, no. (%) 34 (69.4) 19 (65.5) 15 (75.0) .542 18 (64.3) 16 (76.2) .533
Symptom score 3 (3-4) 3 (3-3) 4 (4-5) * 3 (3-4) 3 (3-4) .501
Cumulative threshold dose of
peanut protein (g)
0.1 (0.03-0.63) 0.10 (0.33-1.38) 0.10 (0.03-0.38) .884 0.03 (0.03-0.09) 0.92 (0.37-4.38) *
SPT response to peanut (mm) 9 (7-12) 9 (4-10) 10 (7-13) .102 10 (8-13) 8 (4-11) .021
Specific IgE to peanut (KUA/L) 5.15 (0.51-29.78) 1.86 (0.38-12.85) 23.20 (5.18-94.80) .010 7.17 (1.73-75.80) 1.33 (0.38-12.35) .026
Specific IgE to Ara h 1 (KUA/L) 0.11 (0.02-2.14) 0.09 (0.01-0.23) 0.20 (0.09-11.58) .021 0.18 (0.04-8.67) 0.09 (0.01-0.15) .051
Specific IgE to Ara h 2 (KUA/L) 1.65 (0.20-15.20) 0.68 (0.10-2.67) 10.11 (1.48-41.40) .003 5.05 (1.06-46.80) 0.46 (0.12-7.36) .032
Specific IgE to Ara h 3 (KUA/L) 0.03 (0.01-0.33) 0.03 (0.01-0.13) 0.05 (0.01-0.98) .221 0.04 (0.01-0.89) 0.02 (0.01-0.05) .069
Specific IgE to Ara h 8 (KUA/L) 0.03 (0.01-0.47) 0.03 (0.01-0.23) 0.03 (0.01-1.96) .582 0.03 (0.01-0.28) 0.02 (0.01-2.04) 1.0
Specific IgE to Ara h 9 (KUA/L) 0.01 (0.01-0.02) 0.01 (0.01-0.02) 0.01 (0.01-0.07) .818 0.01 (0.01-0.04) 0.01 (0.01-0.02) .856
No. of major peanut allergens
bound by IgE
2 (1-2) 1.0 (0-2.0) 2.0 (1.0-3.0) .019 2 (1-3) 1 (1-2) .089
Peanut-specific IgG4 (mg/L) 190.0 (120.0-662.5) 160 (120-405) 380 (120-1100) .235 0.14 (0.12-0.80) 0.29 (0.13-0.66) .425
Ratio of peanut-specific
IgG4 to IgE
15.7 (5.7-88.3) 21.63 (5.78-161.23) 11.26 (3.15-76.75) .209 8.6 (2.3-66.1) 48.9 (15.5-159.4) .011
Other food allergy, no. (%) 47 (95.9) 27 (93.1) 20 (100.0) .507 28 (100.0) 19 (90.5) .179
Atopic eczema, no. (%) 40 (81.6) 23 (79.3) 17 (85.0) .720 25 (89.3) 15 (71.4) .146
Asthma, no. (%) 19 (38.8) 11 (37.9) 8 (40.0) 1.0 11 (39.3) 8 (38.1) 1.0
Allergic rhinitis, no. (%) 27 (55.1) 15 (51.7) 12 (60.0) .771 19 (67.9) 8 (38.1) .048
Pollen allergy, no. (%) 14 (28.6) 7 (24.1) 7 (35.0) .524 8 (28.6) 6 (28.6) 1.0
Values are expressed as numbers (percentages) or medians (interquartile ranges). P values < .05 are boldface.
*Values are not indicated because these characteristics formed the basis for classifying the patients into severity and threshold groups (P <. 001).
A
B
FIG 1. Peanut dose response of basophil activation in patients with severe
versus nonsevere reactions (A) and in patients with low versus high
threshold of reactivity (B) to peanut. *P < .05 and **P < .01 for the compar-
ison between groups by using the Mann-Whitney U test.
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II). Similar differences were found when considering discrete
threshold doses (data not shown).Logistic regression analyses to assess different
parameters of severity and threshold
Because parameters other than BAT varied with the severity
and threshold of allergic reactions to peanut (Table I), logistic
regression analyses were conducted to assess which parameters
were independently associated with severity and threshold
(Table III). After multivariable analyses, only the basophil
activation markers were retained for severity and threshold,
meaning that the BAT alone was more discriminative in pre-
dicting the severity (CD63 peanut/anti-IgE, P 5 .001) and
threshold (CD-sens, P 5 .020) of allergic reactions to peanut
than the other allergy tests or the combination of the BAT
with the other allergy tests (Table III). Classifying the severity
of allergic reactions according to the other severity scores and
according to the need for epinephrine resulted in similar find-
ings (data not shown).Basophil activation test cutoffs for severity and
threshold
Basophil activation of 1.3 or greater CD63 peanut/anti-IgE
increased the proportion of severe reactors by 3-fold (relative risk,
3.4; 95% CI, 1.8-6.2) compared with that seen in patients with less
than 1.3 CD63 peanut/anti-IgE (P5 .001; Fig 3, A). Patients with
CD-sens values of 84.0 or greater had an about 2-fold higher
chance of reacting to trace amounts of peanut (relative risk, 1.9;
95% CI, 1.3-2.8) compared with patients with lower CD-sens
values and thus with a higher threshold of reactivity to peanut
(P5.014). BATresult cutoffs to estimate the severity and threshold
of peanut-induced allergic reactions were also determined by using
receiver operating characteristic curve analyses (see Fig E1 in this
article’s Online Repository at www.jacionline.org).
TABLE II. BAT parameters associated with the severity and threshold of allergic reactions to peanut
BAT to peanut
Study population
(n 5 49)
Severity groups Threshold groups
Mild-moderate
(n 5 29) Severe (n 5 20) P value
<_0.1 g Peanut
protein (n 5 28)
>0.1 g Peanut
protein (n 5 21) P value
% CD631 peanut 0.1 0.63 (0-3.05) 0.36 (0-3.05) 1.03 (0.16-3.22) .215 1.07 (0.14-3.34) 0.36 (0-1.43) .140
% CD631 peanut 1 2.38 (0.90-15.44) 2.13 (0.36-8.12) 8.60 (1.68-34.41) .016 3.08 (1.41-39.38) 1.76 (0.68-4.85) .090
% CD631 peanut 10 18.16 (4.45-51.90) 6.65 (2.15-31.73) 37.04 (12.80-70.71) .009 19.33 (4.67-71.52) 15.54 (2.15-36.12) .163
% CD631 peanut 100 21.78 (8.44-51.88) 17.11 (2.60-44.28) 48.44 (16.24-68.79) .003 23.60 (8.73-58.03) 21.78 (1.99-49.36) .505
% CD631 peanut 1,000 23.53 (7.70-43.37) 18.56 (3.37-35.18) 34.33 (20.31-59.27) .049 22.86 (7.70-38.88) 24.57 (3.30-55.36) .818
% CD631 peanut 10,000 34.36 (12.32-55.44) 25.86 (5.74-44.68) 52.79 (28.92-58.93) .012 36.08 (10.96-54.47) 34.36 (10.40-58.37) .888
Mean % CD63 peanut
10-100
16.94 (6.29-52.38) 13.26 (2.56-38.05) 41.31 (10.23-67.36) .012 10.18 (5.16-16.09) 20.41 (4.36-43.42) .419
AUC CD63 peanut 86.96 (46.82-207.38) 66.44 (27.64-164.91) 159.14 (78.84-240.42) .016 92.96 (34.24-231.34) 86.96 (52.84-196.60) .671
Maximal % CD631
to peanut
39.90 (15.20-67.39) 27.74 (9.99-56.23) 59.49 (31.47-75.85) .025 47.59 (15.12-74.75) 34.66 (13.08-62.81) .303
% CD631
peanut/anti-IgE
0.82 (0.32-1.32) 0.53 (0.15-0.85) 1.32 (0.92-1.55) <.001 0.79 (0.44-1.26) 0.83 (0.09-1.35) .716
EC50 (ng/mL) 10 (1-10) 10 (1-100) 10 (1-10) .058 1.0 (1.0-32.5) 10.0 (10.0-10.0) .019
CD-sens 12.97 (1.96-85.91) 5.37 (0.99-50.66) 32.59 (11.62-87.97) .023 32.59 (2.58-113.75) 5.37 (0.80-13.13) .005
Values are expressed as medians (interquartile ranges). Peanut extract concentrations are expressed in ng/mL. EC50 and CD-sens were calculated using the CD63 dose-response.
P values < .05 are boldface.
AUC, Area under the curve.
A
B
FIG 2. Best BAT parameters to distinguish between patients with severe
versus nonsevere reactions (A) and patients with low versus high threshold
of reactivity (B) to peanut. **P < .01 and ***P < .001 for the comparison be-
tween groups by using the Mann-Whitney U test.
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Clinically, symptom score and threshold dose were not
correlated (Rs 5 20.067, P 5 .645, see Table E6 in this arti-
cle’s Online Repository at www.jacionline.org). However, the
basophil markers of severity (CD63 peanut/anti-IgE) and
threshold (CD-sens) were strongly correlated (Rs 5 0.60,
P < .001).DISCUSSION
Currentmanagement of PA relies on allergen avoidance and the
prescription of autoinjectable epinephrine to patients deemed to
be at risk of anaphylaxis. Knowing whether individual patients
are at risk of reacting to trace amounts of the allergen or of having
severe reactions would improve the care for patients with PA.
Previously, we showed that the BAT resembles very closely the
clinical phenotype of patients in terms of clinical reactivity to
peanut.14 In this study we identified allergen-specific basophil
reactivity (as measured by CD63 peanut/anti-IgE) and basophil
sensitivity (as measured by CD-sens) as biomarkers of severity
and threshold of allergic reactions to peanut during OFCs.
This is a prospective study of a well-characterized population of
patients with PA that were submitted to OFCs regardless of the
presence of clinical risk factors for severe reactions and of the SPT
and specific IgE results. In most previous studies patients with a
previous history of anaphylaxis or current asthma and/or with
specific IgE levels of greater than the 95% positive predictive value
cutoff were often excluded, thereby limiting the spectrum of the
disease severity studied.25 Different severity scores have been
adopted in different studies, some including both symptom score
and eliciting dose. We adopted a severity score that was previously
validated18,26 and does not include the dose that caused a reaction
because we aimed to assess these 2 factors, severity and threshold,
independently. Indeed, distinct BAT parameters reflected the
severity and threshold of allergic reactions. The best parameter to
predict severity was the ratio between basophil-specific activation
to allergen and basophil-nonspecific activation to anti-IgE. The
response of basophils of allergic patients to allergen has been re-
ported to be greater than that to anti-IgE or anti-FcεRI.27,28 In a pre-
vious study of childrenwith cow’s milk allergy,28 the ratio between
the percentage of CD63 basophils in response to cow’s milk and to
anti-FcεRIwas higher in patientswith persistent cow’smilk allergy
compared with that in patients who outgrew their allergy and was
correlated with the severity of the reactions during challenges.
In contrast to a study recently published in the Journal,12 in
which BAT results showed no correlation with severity but only
with threshold, in our study BATs informed not only about
TABLE III. Univariable and multivariable analyses of factors associated with the severity and threshold of allergic reactions to
peanut
Variable
Severe allergic reaction Low threshold of reactivity
OR (95% CI) P value OR (95% CI) P value
Univariable analysis
% CD631 peanut/anti-IgE 0.111 (0.026-0.478) .001 — —
CD-sens — — 1.027 (1.004-1.050) .020
SPT — — 1.231 (1.033-1.466) .020
Specific IgE to peanut 1.014 (1.0-1.029) .056 1.022 (1.0-1.045) .053
Specific IgE to Ara h 1 1.031 (0.985-1.079) .186 1.016 (0.975-1.058) .459
Specific IgE to Ara h 2 1.034 (0.999-1.070) .054 1.036 (0.994-1.080) .090
Specific IgE to Ara h 3 — — 3.391 (0.590-19.501) .171
No. of major peanut allergens bound by IgE 2.342 (1.144-4.791) .020 1.712 (0.896-3.272) .104
Peanut-specific IgG4/IgE ratio — — 0.999 (0.997-1.001) .283
Allergic rhinitis — — 3.431 (1.049-11.222) .041
Multivariable analysis*
% CD631 peanut/anti-IgE 0.111 (0.026-0.478) .001 — —
CD-sens — — 1.027 (1.004-1.050) .020
*All variables were retested by using forward multivariable logistic regression, and only variables contributing to the model (P < .05) were retained. CD-sens refers to CD-sens
values calculated by using the CD63 dose response. P values < .05 are boldface.
A
B
FIG 3. A, Proportion of patients with severe reactions according to the 75th
percentile of basophil reactivity (measured by CD63 peanut/anti-IgE). B,
Proportion of patients with lower threshold of reactivity to peanut accord-
ing to the 75th percentile of basophil sensitivity (measured by using CD-
sens). *P 5 .05 and **P < .01 for the comparison between groups by using
the Mann-Whitney U test.
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OFCs. Although different severity scores were primarily used, in
both studies findings were confirmed with other severity scores;thus the severity scores used were unlikely to have accounted
for the discrepancy between results. These differences might be
explained by the adopted OFC protocol. In the cited study OFCs
were performed over 2 days, with 2-hour intervals between doses
up to a cumulative dose of 4.443 g of peanut protein. In our study
OFCswere performed on a single daywith 20-minute intervals be-
tween doses, and the cumulative dose for children older than 3
years was 9.35 g. These factors could have contributed to the
greater severity of reactions we observed during OFCs, enabling
us to find a biomarker for severity. We also found stronger corre-
lations for threshold and additionally performed logistic regres-
sion analyses and determined cutoffs both for severity and
threshold.
It should be noted in our study that a single-day challenge
protocol is performed in which placebo and active doses are
interspersed. This is not in keeping with the recent PRACTALL
guidelines29 but is in keeping with the LEAP study–recommended
challenge procedure to peanut (NCT00329784).16,30 This is done
for pragmatic reasons because a large number of children come
from further afield in the United Kingdom, and it is difficult for
them to come in for a 2-day OFC program. On the rare occasion
that a child reacts after a placebo dose, then a 2-day DBPCFC is
performed in which placebo doses are administered on one day
and active doses on the other day. Only 2 of 52 patients with pos-
itive challenge results in the study initially reacted after placebo on
a mixed active-placebo 1-day protocol, and both these patients had
their diagnosis of PA subsequently confirmed by using a 2-day
DBPCFC.
With respect to SPT responses and serum specific IgE levels to
peanut possibly reflecting the severity of allergic reactions to
peanut, previous studies showed contradictory results, with some
showing that SPT responses and serum specific IgE levels
predicted the development of anaphylaxis6,31-33 and others not
finding any association between allergy test results and the
severity of allergic reactions.4,25 In our study, patients with severe
reactions had higher levels of specific IgE to peanut, Ara h 1, and
Ara h 2. Severity has also been associated with a greater number
of peanut allergens34,35 and epitopes36 recognized by patients’
IgE and with the intensity of bands on immunoblotting as a surro-
gate for antibody affinity and avidity.34 Our study corroborates
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directed to a larger number of peanut major allergens compared
with patients with mild-to-moderate reactions. Interestingly, pa-
tients with a higher ratio of peanut-specific IgG4 to IgE reacted
to higher doses of peanut, suggesting that IgG4 competed with
IgE for binding to the allergen, blocking its effect and preventing
degranulation of basophils at a low PE concentration. One of the
advantages of the BAT is that it is a functional assay that takes into
account all these factors, including levels, specificity, diversity,
and affinity of allergen-specific IgE and even possible interfer-
ence by other allergen-specific antibodies, which together are
responsible for allergen-induced effector cell activation. There-
fore the BAT has a greater potential to reflect the allergic reaction
as it happens in vivo than methods that test these IgE parameters
separately. This is reflected in our data in which, after multivari-
able analyses, BAT parameters proved to be more predictive of
severity and threshold of allergic reactions than the other tests.
A relationship between severity and threshold has previously
been suggested,37 with patients who react to lower doses being
more at risk of severe symptoms. In our study and others12,38
the clinical parameters of severity and threshold were not corre-
lated. However, a strong correlation was found for the respective
basophil parameters. This discrepancy could be due to the fact
that during the BAT, the ‘‘in vitro challenge’’ can progress to
higher doses, whereas the in vivo OFC is typically stopped with
the first allergic symptoms and signs. Allergic reactions during
OFCs might have been different if a large dose had been
consumed at once. The fact that basophil activation can be deter-
mined up to high doses of allergen regardless of disease severity is
another clear advantage of the BAT as a biomarker of disease
severity.
We identified BAT markers of severity and threshold of
reactions during OFCs, but they might not reflect the severity
and threshold of allergic reactions in the community. Hourihane
et al33 showed that the challenge score correlated with the most
recent reaction but not with the most severe reaction in the com-
munity, suggesting that a patient’s reactivity to peanut changes
over time. Cofactors that can increase the severity of allergic re-
actions (eg, uncontrolled asthma, viral infections, menstruation,
exercise, consumption of alcohol or drugs, and psychological fac-
tors) might be present in the community and are usually
controlled during OFCs. Also, with respect to threshold, there
might be some variation because the eliciting dose during OFCs
can be underestimated because the patient feels safe during the
OFC but can also be overestimated because mild symptoms
would remain unnoticed in the community.22 Severity and elicit-
ing dose during challenges have not been reproducible in other
studies.39,40
The utility of the BATas a marker for severity and threshold of
allergic reactions is to provide additional information to the
patients and should be interpreted in light of the clinical history
and presence of other risk factors. The management of patients
should continue to be based on patient education, and the
importance of an emergency treatment plan and appropriate
training cannot be overemphasized, regardless of the magnitude
of allergy test results, including those of the BAT. However, the
BAT can be used to identify patients who are at risk of reacting to
small amounts of the allergen and of having severe symptoms
that require special attention. Further validation of these
objective BAT markers in different populations repeated at
different time points might allow us to identify the subset ofhigh-risk children with PAwho require closer monitoring, as well
as the subgroup of children whose allergy to peanut might
spontaneously resolve. Identification of high-risk groups should
not be based only on biological markers but also on psychosocial,
demographic, behavioral, and clinical parameters. Future studies
on the stability of BAT results over time and during different
periods of the year (eg, hay fever season and asthma exacerba-
tions) would be most informative. Although BAT parameters
might not completely distinguish between those patients with
severe reactions who respond to a low threshold of reactivity and
those with milder reactions and a higher threshold dose, they
could prove to be far more accurate in discriminating changes in
the clinical threshold and severity in the same subjects over time.
It has already been shown that BAT results to peanut, egg, and
milk decrease in patients who have undergone oral immuno-
therapy.41-43 It would be of great value to look at the stability of
BAT results over time in untreated patients and at the change in
BAT parameters in patients undergoing oral immunotherapy to
foods and compare this with posttreatment challenge outcome
measures.
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Clinical implications: The BAT can be used as an in vitro surro-
gate for OFCs to estimate the severity and threshold of allergic
reactions and improve the management of patients with PA.REFERENCES
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